Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could lift bipolar depression

NCT ID NCT06605599

Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called ABBV-932 in 161 adults with bipolar I or II disorder who were experiencing a depressive episode. Participants took either the drug or a placebo daily for 6 weeks. Researchers measured changes in depression symptoms using standard rating scales. The trial is now complete, and results will show if the drug is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ABBV-932 (oral capsule)
What this could lead to
If it works, this could provide a new treatment option for depressive episodes in people with bipolar disorder.
What could go wrong
This is an early Phase 2 trial with only 161 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

161 people

The number who actually took part.

Started

Oct 2024

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for bipolar I or II disorder without psychotic features based on the Mini International Neuropsychiatric Interview (MINI), with a current depressive episode of at least 4 weeks and not exceeding 12 months. * Have a minimum score of 20 on the 17-item Hamilton Depression Rating Scale (HAMD-17). * Have a minimum score of 2 on Item 1 of the HAMD-17 at screening. Exclusion Criteria: * Positive urine drug screen (UDS) result at screening. * Treated with any investigational drug within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug, is currently enrolled in another clinical study, or was previously enrolled in this study. * Current use of any antipsychotic, antidepressant, anticonvulsant, mood stabilizer, herb, or over-the-counter medication with psychoactive potential within 1 week or 5 half-lives of the medication (whichever is longer). * Prior exposure to ABBV-932 within 90 days prior to baseline.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipolar I disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bipolar disorder bipolar I disorder bipolar II disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bipolar I disorder Bipolar ii disorder

Contacts and locations

Locations

  • Accel Research Sites Network - St. Pete /ID# 267463

    Largo, Florida, 33777, United States

  • Advanced Research Center /ID# 267716

    Anaheim, California, 92805, United States

  • Alliance for Research Alliance for Wellness /ID# 267492

    Long Beach, California, 90807, United States

  • Allied Biomedical Res Inst Inc /ID# 267481

    Miami, Florida, 33155, United States

  • Arch Clinical Trials /ID# 267507

    St Louis, Missouri, 63125, United States

  • Axiom Research /ID# 267518

    Colton, California, 92324, United States

  • BDH Research /ID# 267025

    San Juan, 00927, Puerto Rico

  • Benchmark Research /ID# 267626

    Shreveport, Louisiana, 71101, United States

  • Bio Behavioral Health /ID# 267493

    Toms River, New Jersey, 08755, United States

  • CenExel /ID# 267675

    Gaithersburg, Maryland, 20877-1407, United States

  • Center For Emotional Fitness - Cherry Hill /ID# 267661

    Cherry Hill, New Jersey, 08002, United States

  • Coastal Carolina Research Center, LLC /ID# 267550

    Charleston, South Carolina, 29492, United States

  • Collaborative Neuroscience Research - Garden Grove /ID# 267654

    Garden Grove, California, 92845, United States

  • Core Clinical Research /ID# 268534

    Everett, Washington, 98201, United States

  • Duplicate_Oasis Clinical Research, LLC /ID# 267969

    Las Vegas, Nevada, 89121, United States

  • Excell Research /ID# 267541

    Oceanside, California, 92056, United States

  • FutureSearch Trials of Dallas /ID# 267715

    Dallas, Texas, 75231, United States

  • GMI Florida - Central Miami Medical Institute /ID# 267566

    Miami, Florida, 33125, United States

  • Grayline Research Center /ID# 267466

    Wichita Falls, Texas, 76309, United States

  • Harmonex /ID# 267504

    Dothan, Alabama, 36303, United States

  • INSPIRA Clinical Research /ID# 267041

    San Juan, 00918-3014, Puerto Rico

  • Instituto De Neurologia Dra. Ivonne Fraga, Psc /ID# 267065

    San Juan, 00918, Puerto Rico

  • K2 Medical Research - Orlando - South Orlando Avenue /ID# 267567

    Orlando, Florida, 32751, United States

  • Kaku Mental Clinic /ID# 268020

    Fukuoka, 810-0022, Japan

  • Kawamura Mental Clinic /ID# 268325

    Sapporo, Hokkaido, 001-0023, Japan

  • Kokura Mental Clinic /ID# 268031

    Kitakyushu, Fukuoka, 802-0006, Japan

  • Kuramitsu Hospital /ID# 268751

    Fukuoka, 819-0037, Japan

  • Lehigh Center for Clinical Research /ID# 267451

    Allentown, Pennsylvania, 18103, United States

  • Neurobehavioral Research /ID# 267564

    Cedarhurst, New York, 11516, United States

  • New Hope Clinical Research - Inpatient unit /ID# 267465

    Charlotte, North Carolina, 28211, United States

  • Northwest Clinical Research Center /ID# 267505

    Bellevue, Washington, 98007, United States

  • OSU Psychiatry Department /ID# 267730

    Columbus, Ohio, 43210, United States

  • Perceptive Pharma Research /ID# 267563

    Richmond, Texas, 77407, United States

  • Quest Therapeutics of Avon Lake /ID# 267558

    Avon Lake, Ohio, 44012, United States

  • Segal Trials - West Broward Outpatient Research Site /ID# 267947

    Tamarac, Florida, 33319-4985, United States

  • Sooner Clinical Research /ID# 267639

    Oklahoma City, Oklahoma, 73116, United States

  • Suburban Research Associates - Media /ID# 267621

    Media, Pennsylvania, 19063, United States

  • Sun Valley Research Center /ID# 267708

    Imperial, California, 92251, United States

  • Viking Clinical Research Center - Temecula /ID# 267634

    Temecula, California, 92591, United States

  • Yutaka Clinic /ID# 268026

    Sagamihara, Kanagawa, 252-0303, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.